Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 4, 2007, Pages 412-421

  Chiang, Chi Wen ^a,b   Chen, Chi Yu ^c   Chiu, Hui Fen ^a   Wu, Hsin Lung ^a   Yang, Chun Yuh ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antihypertensive drugs; Diabetes; Hypertension; Prescribing patterns; Prescribing rates; Trends

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG TARGETING; DRUG USE; FEMALE; GENE TARGETING; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NATIONAL HEALTH INSURANCE; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TAIWAN;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; COMORBIDITY; CROSS-SECTIONAL STUDIES; DATABASES; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; OUTPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; TAIWAN; TIME FACTORS;

EID: 34247537449     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1322     Document Type: Article

References (66)

1. Tai TY, Chuang LM, Chen CJ, Lin BJ. Link between hypertension and diabetes mellitus epidemiological study of Chinese adults in Taiwan. Diabetes Care 1991; 14: 1013-1020.
2. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In National Diabetes Data Group: Diabetes in America (2nd edn). Govt. Printing Office: Washington, DC, 1995; 429-448. (NIH publ. no. 95-1468).
3. Williams R, van Gaal L, Lucioni C. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 2002; 45: S13-S17.
4. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003; 25: 1017-1038.
5. Lin T, Chou P, Tsai ST, Lee YC, Tai TY. Predicting factors associated with costs of diabetic patients in Taiwan. Diabetes Res Clin Pract 2004; 63: 119-125.
6. Curb JD, Pressel SL, Cutler JA, et al. for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-1892.
7. Staessen JA, Fagard R, Thijs L, et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.
8. Zuanetti G, Latini R, Maggioni AP, Franzosi M. Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997; 96: 4239-4245.
9. UK Prospective Diabetes Study Group. Tight blood pressure and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
10. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
11. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
12. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
13. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
14. American Diabetes Association. Treatment of hypertension in adults with diabetes (Position Statement). Diabetes Care 2002; 25 (Suppl. 1): S71-S73.
15. American Diabetes Association. Treatment of hypertension in adults with diabetes (Position Statement). Diabetes Care 2003; 26 (Suppl. 1): S80-S82.
16. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
17. Feldman RD, Campbell N, Larochelle P, et al. 1999 Canadian recommendations for the management of hypertension. Task force for the development of the 1999 Canadian recommendations for the management of hypertension. CMAJ 1999; 161(Suppl. 12): S1-S17.
18. Ramsay L, Williams B, Johnston G, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-592.
19. Bakris GL, Williams M, Dworkin L, et al. For the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646-661.
20. Psaty BM, Koepsell TD, Yanez ND, et al. Temporal patterns of antihypertensive medication use among older adults, 1989 through 1992. An effect of the major clinical trials on clinical practice? JAMA 1995; 273: 1436-1438.
21. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995; 155: 829-837.
22. Monane M, Glynn RJ, Gurwitz JH, Bohn RL, Levin R, Avorn J. Trends in medication choices for hypertension in the elderly. The decline of the thiazides. Hypertension 1995; 25: 1045-1051.
23. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? JAMA 1997; 278: 1745-1748.
24. Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension 2000; 36: 600-603.
25. Wolf HK, Andreou P, Bata IR, et al. Trends in the prevalence and treatment of hypertension in Halifax County from 1985 to 1995. CMAJ 1999; 161: 699-704.
26. Bourgault C, Rainville B, Suissa S. Antibypertensive drug therapy in Saskatchewan: patterns of use and determinants in hypertension. Arch Intern Med 2001; 161: 1873-1879.
27. Al Khaja KAJ, Sequeira RP, Wahab AW, Mathur VS. Anti-hypertensive drug prescription trends at the primary health care centres in Bahrain. Pharmacoepidemiol Drug Saf 2001; 10: 219-227.
28. Adigun AQ, Ishola DA, Akintomide AO, Ajayi AA. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs. J Hum Hypertens 2003; 17: 277-285.
29. Yusuff KB, Balogun OB. Pattern of drug utilization among hypertensives in a Nigerian teaching hospital. Pharmacoepidemiol Drug Saf 2005; 14: 69-74.
30. Bog-Hansen E, Lindblad U, Ranstam J, Melander A, Rastam L. Antihypertensive drug treatment in a Swedish community: Skaraborg Hypertension and Diabetes Project. Pharmacoepidemiol Drug Saf 2002; 11: 45-54.
31. Al Khaja KAJ, Sequeira RP, Mathur VS. Prescribing patterns and therapeutic implications for diabetic hypertension in Bahrain. Ann Pharmacother 2001; 35: 1350-1359.
32. Al Khaja KAJ, Sequeira RP, Mathur VS, Damanhori AH, Abdul Wahab AW. Family physicians' and general practitioners' approaches to drug management of diabetic hypertension in primary care. J Eval Clin Pract 2002; 8: 19-30.
33. Supina AL, Guirguis LM, Majumdar SR, et al. Treatment gaps for hypertension management in rural Canadian patients with type 2 diabetes mellitus. Clin Ther 2004; 26: 598-606.
34. Gulliford MC, Charlton J, Latinovic R. Trends in antihypertensive and lipid-lowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion? J Hum Hypertens 2005; 19: 111-117.
35. Cheng SF, Hsu HH, Lee HS, Lin CS, Chou YC, Tien JH. Rational pharmacotherapy in the diabetic hypertension: analysis-prescribing patterns in a general hospital in Taiwan. J Clin Pharm Ther 2004; 29: 547-558.
36. Bureau of National Health Insurance. Available from http://www.nhi.gov.tw/english/index.asp. Acceseed 10 May 2005.
37. WHO Collaborating Center for Drug Statistics Methodology. ATC Index with DDDs 2003. WHO: Oslo, 2003.
38. Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
39. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652.
40. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-684.
41. Wang JG, Staessen JA, Gong L, Liu L. for the Systolic Hypertension in China (Syst-China) Collaborative Group. Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med 2000; 160: 211-220.
42. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-2997.
43. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
44. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
45. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
46. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
47. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE sub-study. Lancet 2000; 355: 253-259.
48. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/ beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001; 24: 2091-2096.
49. Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cordiol 1998; 82: 9R-14R.
50. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (Suppl. 2): B54-B64.
51. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
52. Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000; 18: 1671-1675.
53. Schrier RW, Estacio RO, Esler A, Meheler P, Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-1097.
54. Lindoholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 1004-1010.
55. Bureau of Health Promotion. Department of Health, Taiwan, R.O.C. Available from http://www.bhp.doh.gov.tw/BBP/do/chinese/home. Accessed 21 Nov 2005.
56. Taiwan Society of Nephrology. Available from http://www.tsn.org.tw/. Accessed 21 Nov 2005.
57. Yang WC, Hwang SJ, Chiang SS, Chen HF, Tsai ST. The impact of diabetes on economic costs in dialysis patients: experiences in Taiwan. Diabetes Res Clin Pract 2001; 54 (Suppl. 1): S47-S54.
58. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995; 40: 141-144.
59. Lee YJ, Tsai JC. Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus. Metabolism 2001; 50: 1346-1350.
60. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996; 276: 785-791.
61. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cordiol 1996; 77:12b-16b.
62. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/ calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283-1289.
63. Schneider M, Lerch M, Papiri M, et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens 1996; 14: 669-677.
64. Teuscher AU, Weidmann PU. Requirements for antihypertensive therapy in diabetic patients: metabolic aspects. J Hypertens 1997; 15 (Suppl. 2): S67-S75.
65. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1997; 20(1S): 5S-13S.
66. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2001; 24(Suppl. 1): S33-S43.